|Assessment Status||Rapid Review Complete|
|Indication||Dapagliflozin (Forxiga®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%.|
|Rapid review commissioned||11/10/2023|
|Rapid review completed||21/11/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that dapagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.